- The study addressed the undefined molecular programs linking immune responses to motor neuron pathology in ALS.
- Researchers used an integrated approach combining single-cell, bulk RNA sequencing, and spatial proteogenomics.
- Findings revealed broad immune remodeling in C9orf72 ALS and subtype-specific monocyte activation and CD8 T cells.
- The authors concluded that immune alterations contribute to ALS heterogeneity and link blood changes to spinal cord damage.
- This suggests stratified immunomodulation as a potential therapeutic strategy for personalized ALS treatments.
Unraveling Immune Contributions to Amyotrophic Lateral Sclerosis Progression
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder defined by the progressive loss of motor neurons. While its etiology is complex, neuroinflammation is a recognized hallmark, with factors like APOE genotype influencing the immune response [1, 2]. This process involves a dynamic interplay between immune cells and the central nervous system that can affect neuronal health and disease trajectory, partly through metabolic regulation [3, 4]. Although strategies like mesenchymal stem cell therapies are being investigated for their immunomodulatory potential [5, 6, 7, 8], the specific molecular links between immune activity and motor neuron pathology have been unclear. A recent study provides a more detailed map of these immune dynamics, connecting peripheral immune alterations to pathological events within the central nervous system [9].
Integrated Approach to Immune Profiling in ALS
To dissect the immune landscape of Amyotrophic Lateral Sclerosis (ALS), investigators utilized a multi-modal strategy designed to capture a comprehensive view of both systemic and central nervous system processes. The study integrated single-cell RNA sequencing, a method for analyzing gene expression in individual cells, with bulk RNA sequencing, which provides an average measure of gene expression across a tissue sample. This was complemented by spatial proteogenomics, a technique that maps the location of proteins and gene transcripts directly within tissue sections, preserving the anatomical context of molecular events. This combined methodology allowed the researchers to characterize both shared and distinct immune dynamics in peripheral blood and spinal cord tissues from two distinct patient cohorts: individuals with sporadic ALS and those carrying C9orf72 repeat expansions, one of the most common genetic causes of the disease. This stratification was essential for exploring the biological basis of ALS heterogeneity.
Subtype-Specific Immune Signatures Emerge
The analysis revealed distinct immune profiles that varied by ALS subtype and disease progression. The researchers found broad immune remodeling in patients with C9orf72 ALS, suggesting a particularly pronounced and widespread alteration of the immune system in this genetic form of the disease. More specifically, the study identified subtype-specific and progression-associated differences in monocyte activation. This indicates that these key innate immune cells behave differently in sporadic versus C9orf72 ALS, and their activation state appears to evolve as the disease advances. In the adaptive immune system, the findings pointed to a targeted response rather than generalized inflammation. Investigators observed differences in antigen-experienced CD8 effector memory T cells that were also specific to ALS subtype and disease progression. Crucially, these T cells showed clonal features consistent with an antigen-driven response, meaning specific T cell populations had expanded as if reacting to a particular molecular target, a process that could directly contribute to neurodegeneration.
Localizing Immune Activity to ALS Pathology
By mapping molecular changes directly within spinal cord tissue, the study established a direct physical link between immune activity and sites of neurodegeneration. The analysis showed that complement activation, a cascade of inflammatory proteins that can tag cells for elimination, converged specifically at sites of motor neuron loss. This finding spatially connects a key arm of the innate immune system to the defining pathological outcome of Amyotrophic Lateral Sclerosis (ALS). This immune activity was also co-localized with another core feature of the disease. The complement activation was found to converge at sites of TDP-43 pathology, the abnormal protein aggregates present in the majority of ALS cases. Furthermore, the researchers identified lipid-programmed myeloid states, referring to immune cells like microglia and macrophages whose function is altered by local lipid metabolism, also converging at these same sites of motor neuron loss and TDP-43 pathology. This convergence reinforces that specific immune and metabolic programs are active precisely where neuronal injury is occurring.
Clinical Implications for Stratified Immunomodulation
These findings connect peripheral immune signatures in the blood to specific pathological events in the spinal cord, providing a biological basis for the heterogeneity observed in Amyotrophic Lateral Sclerosis (ALS). The primary clinical implication is the potential for stratified immunomodulation as a therapeutic strategy. Rather than a single immune-based treatment for all patients, this research suggests that therapies could be tailored to an individual's disease subtype and specific immune profile. For example, the distinct monocyte and T cell activities observed between sporadic and C9orf72 ALS may indicate that different immunomodulatory agents would be required for each group. By defining the molecular programs driving inflammation in different patient populations, this work provides a rationale for developing and testing targeted therapies aimed at the specific immune pathways contributing to disease progression.
References
1. Savran Z, Baltaci SB, Aladag T, Mogulkoc R, Baltaci AK. Vitamin D and Neurodegenerative Diseases Such as Multiple Sclerosis (MS), Parkinson's Disease (PD), Alzheimer's Disease (AD), and Amyotrophic Lateral Sclerosis (ALS): A Review of Current Literature.. Current nutrition reports. 2025. doi:10.1007/s13668-025-00663-y
2. Fernández‐Calle R, Konings SC, Frontiñán-Rubio J, et al. APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases. Molecular Neurodegeneration. 2022. doi:10.1186/s13024-022-00566-4
3. Polazzi E, Mengoni I, Caprini M, Peña‐Altamira E, Kurtys E, Monti B. Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity. Neurosignals. 2012. doi:10.1159/000337115
4. Hu T, Liu C, Lei M, et al. Metabolic regulation of the immune system in health and diseases: mechanisms and interventions. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01954-6
5. Vinski D, Vinski NC, Kusumo S, Siagian C. Mesenchymal Stem Cell Combination Therapy Via Intravenous and C-Arm– Guided Spinal Delivery: A Systematic Review and Meta-Analytic Framework For Neurological and Functional Recovery. Journal Of World Science. 2026. doi:10.58344/jws.v5i4.1662
6. Krull AA, Setter DO, Gendron TF, et al. Alterations of mesenchymal stromal cells in cerebrospinal fluid: insights from transcriptomics and an ALS clinical trial.. Stem cell research & therapy. 2021. doi:10.1186/s13287-021-02241-9
7. Han X, Liao R, Li X, et al. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies. Signal Transduction and Targeted Therapy. 2025. doi:10.1038/s41392-025-02313-9
8. Essa SM, Khosa NA, Kakar A, Öztürk B, Ibrahim IA, Haq N. Unraveling the Potential of Stem Cell Therapy in Motor Neuron Disease: A Narrative Review.. CNS & neurological disorders drug targets. 2025. doi:10.2174/0118715273382519250918103218
9. Zhang Z, Olst LV, Alessandrini F, et al. Integrated single-cell and spatial transcriptomic profiling in ALS uncovers peripheral-to-central immune infiltration and reprogramming.. Nature neuroscience. 2026. doi:10.1038/s41593-026-02300-5